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Introduction

Methods

ESWL is a clinical therapy to break down kidney and uretal stones into smaller
fragments that are more easily eliminated through the urinary tract. High-energy
shock waves are focused on the stone to cause shear stress and cavitation bubbles
which synergistically ablate the stones. While ESWL is the preferred treatment for
kidney stones over invasive surgeries, the repetitive shock waves necessary to break
up the stones may also cause damage to the renal vasculature endothelium and that
can lead to chronic hypertension [1]. Previous studies have found that ESWL can
cause endothelial dysfunction which is characterized decreased nitric oxide (NO)
bioavailability and increased production of reactive oxygen species (ROS) such as
superoxide (O2-) [2]. Normally, endothelial nitric oxide synthase (eNOS) is in a coupled
state which forms NO in the presence of essential cofactor tetrahydrobiopterin (BH4)
and molecular oxygen. Oxidative stress, such as that caused by ESWL-induced ROS,
can cause BH4 to be oxidized to dihydrobiopterin (BH2). When the BH2:BH4 ratio is
increased, eNOS becomes uncoupled and produces O2- instead of NO [2, 3] (Figure 1).
O2- is short-lived and converted to hydrogen peroxide (H2O2) in blood by superoxide
dismutase. Protein kinase C epsilon (PKCε) has previously been found to regulate
eNOS activity via phosphorylation at serine-1177. Cell-permeable PKCε peptide
activator (PKCε+) increases eNOS activity while PKCε inhibitor (PKCε-) reduces eNOS
activity [2]. Using a combination of eNOS cofactors BH4 or BH2 with eNOS activity
regulators PKCε+ or PKCε-, we can explore the role of modulating eNOS to reduce
oxidative stress and endothelial dysfunction caused by ESWL.

Male Sprague-Dawley rats (275-325g, Charles River, Springfield, MA) were
anesthetized with an induction dose of sodium pentobarbital (60 mg/kg)
intraperitoneally. A maintenance dose (30 mg/kg) was administered at intervals of 45
minutes unless otherwise required. The rat also received sodium heparin (1000 USP
units/mL) i.p. to act as an anticoagulant. The rat’s left external jugular vein was
exposed and catherized with a 24-gauge angio-catheter for drug or saline infusion
post-ESWL treatment. The rat was then subjected to a mid-line laparotomy, and the
left renal vein was isolated. A 22-gauge angio-catheter was inserted into the left renal
vein in direct opposition of the blood flow. A NO or H2O2 microsensor was inserted
into the renal vein catheter and connected to the TBR 4100 Free Radical Analyzer
(World Precision Instruments, Inc., Sarasota, FL) which produces a trace showing realtime measurements of NO or H2O2 release recorded in picoamps (pA). The
microsensors receive an electrical signal proportional to the free radical
concentration through an oxidation/reduction reaction. Baseline measurements
were then taken until a stable baseline (i.e., 300 pA decrease per 300 seconds) was
achieved. Thereafter, the baseline was set to a “zero” reading, and all measurements
post-ESWL were expressed as relative change from baseline. Once a stable baseline
was established, ESWL treatment was initiated by a Dornier Epos Ultra Lithotripter
(1000 shocks, 500 at 60 beats/min, 500 at 120 beats/min, 16kV, 1.3mHz). To simulate
conditions in the no-ESWL control group, the approximate time of treatment (13
min) was maintained without ESWL treatment. Immediately following ESWL or at the
same time for no-ESWL controls, 0.5 mL of saline or drug bolus was infused through
the jugular vein canulation followed by a 0.5mL saline flush. Experimental groups
included combinations of PKCε+ (N-Myr-HADPIGYD, 1097 g/mol, Genemed
Synthesis) or PKCε- (N-Myr-EAVSLKPT, 1054 g/mol, Genemed Synthesis) with BH4
(314 g/mol, Cayman Chemicals) or BH2 (239 g/mol, Cayman Chemicals). Recordings
of NO and H2O2 release were taken throughout the experiment (baseline, ESWL end,
30 min post-ESWL). The microsensors were calibrated prior to each experiment in
order to create a standard calibration curve via a stepwise dose-response to the
appropriate standard solution. NO readings in pA were converted to nanomoles/L
(nM), and H2O2 readings in pA were converted to micromoles/L (µM).

Coupled eNOS

Results

Figure 3. Effect of PKCε+ Combined with BH4 or BH2 on Real-Time Blood NO and H2O2 Release
after ESWL. ESWL significantly decreased NO release and increased H2O2 release (5-30 mins
post-ESWL) compared to no-ESWL controls. Administration of PKCε+/BH4 after ESWL was similar
to no-ESWL controls, significantly increasing NO and decreasing H2O2release (5-30 mins postESWL) compared to ESWL controls. Post-ESWL infusion of PKCε+/BH2 was similar to the ESWL
control group in both NO and H2O2 release. (*p≤0.05, **p≤0.01, compared to ESWL controls)
(#p≤0.05, ##p≤0.01, compared to ESWL with PKCε+/BH2)

Uncoupled eNOS

Figure 1. Coupled eNOS and Uncoupled eNOS. BH4 is the cofactor of coupled eNOS which
results in NO production. ESWL-induced oxidative stress results in an increased BH2:BH4 ratio.
BH2 is the cofactor for uncoupled eNOS which produces O2- and subsequently H2O2.

Figure 4. Effect of PKCε- Combined with BH4 or BH2 on Real-Time Blood NO and H2O2 Release
after ESWL. Post-ESWL infusions of PKCε-/BH4 or PKCε-/BH2 are both similar to no-ESWL
controls, significantly increasing NO release (5-30 mins) and decreasing H2O2 release (15-30
mins) compared to ESWL controls. (*p≤0.05, **p≤0.01, compared to ESWL controls)

Conclusions
Figure 2. The rat was placed supine on a working board with the left kidney in the focal point of
the lithotripter. The microsensor was supported by a catheter in the left renal vein, and the
microsensor tip was positioned so that it was in direct contact with the renal vein blood flow.

Figure 2. Sources of ROS and the Role of PKCε. NADPH Oxidase releases O2- from leukocytes and
endothelial cells. Mitochondria releases O2- via incomplete oxidative phosphorylation.
Uncoupled eNOS releases O2- in the presence of BH2. Increased O2- quenches NO produced
from coupled eNOS to produce ROS such as peroxynitrite (ONOO-) which reduces NO
bioavailability and further increases oxidative stress. PKCε+ increases coupled and uncoupled
eNOS activity, and PKCε- decreases coupled and uncoupled eNOS.

Hypothesis

Experimental Groups:
Nitric Oxide (NO)
1. No-ESWL with Saline (Control) (n=6)
2. ESWL with Saline (Control) (n=5)
3. ESWL with PKCε+/BH4 (n=5)
(0.9 mg/kg; 0.8 mg/kg)
4. ESWL with PKCε+/BH2 (n=5)
(0.9 mg/kg; 2 mg/kg)
5. ESWL with PKCε-/BH4 (n=5)
(0.8 mg/kg; 0.8 mg/kg)
6. ESWL with PKCε-/BH2 (n=5)
(0.8 mg/kg; 2 mg/kg)

Hydrogen Peroxide (H2O2)
7. No-ESWL with Saline (Control) (n=6)
8. ESWL with Saline (Control) (n=6)
9. ESWL with PKCε+/BH4 (n=5)
(0.9 mg/kg; 0.8 mg/kg)
10. ESWL with PKCε+/BH2 (n=5)
(0.9 mg/kg; 2 mg/kg)
11. ESWL with PKCε-/BH4 (n=5)
(0.8 mg/kg; 0.8 mg/kg)
12. ESWL with PKCε-/BH2 (n=5)
(0.8 mg/kg; 2 mg/kg)

ESWL treatment decreased NO and increased H2O2 blood levels compared to noESWL controls. This supports our hypothesis and previous findings in this lab that
ESWL causes oxidative stress and reduced NO bioavailability. Post-ESWL PKCε+/BH4
significantly attenuated the adverse effects of ESWL by increasing NO and decreasing
H2O2 release compared to ESWL+saline. This suggests that this combination enhances
eNOS in its coupled state. Whereas, post-ESWL PKCε+/BH2 was similar to ESWL
control in H2O2 and NO, suggesting that BH2 is nearing saturation to the eNOS binding
site. In contrast, post-ESWL PKCε- with either BH4 or BH2 resulted in increased NO
and decreased H2O2 compared to ESWL+saline. This suggests that PKCε- attenuates
eNOS uncoupled activity after ESWL. Potentially, this study can help to develop
therapeutic uses for PKCε+/BH4 or PKCε- in the attenuation of vascular endothelial
dysfunction following ESWL treatment and possibly eliminate or reduce the acute
renal complications that may lead to chronic conditions such as hypertension.
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